PURPOSE: To evaluate which is the best route of administration for cell therapy in experimental rat model of small-for size syndrome. METHODS: A total of 40 rats underwent partial hepatectomy (70%) that induces the small-for-size syndrome and were divided into four groups of route administration: intravenous, intraperitoneal, enteral and tracheal. The small-for-size syndrome model was designed with extended partial hepatectomy (70%). The animals were divided into four groups of routes administration: intravenous (n=10) - intravenously through the dorsal vein of the penis; intraperitoneal (n=10) - intraperitoneally in the abdominal cavity; enteral (n=10) - oroenteral with the placement of a number 4 urethral probe and maintained at third duo...
Background: The incidence of oesophageal adenocarcinoma (OAC) continues to rise rapidly. There is a ...
Introduction. The aim of this study was to evaluate techniques and establish an optimal method for m...
AIM: To compare therapeutic responses of a vascular-disrupting-agent, combretastatin-A4-phosphate (C...
PURPOSE: Development of a lethal model of peritonitis to assess the results of treating that periton...
Aim: This study aimed to create a peritoneal metastasis (PM) model in Wistar albino rats and nude mi...
PURPOSE: To evaluate the biodistribution of sodium pertecnetate (Na99mTcO4) in organs and tissues, t...
There are many limitations for conducting liver disease research in human beings due to the high cos...
The small bowel transplantation (SBT) represents reasonable alternative to ultimate total parenteral...
Objectives: Presently, the results of small bowel transplantation (SBT) procedures are far from idea...
BACKGROUND/AIMS: In the animal model of auxiliary partial liver transplantation in the rat, the majo...
Contains fulltext : 80074.pdf (publisher's version ) (Closed access)Liver metastas...
Background: Peritoneal carcinomatosis is an unmet medical need. Intraperitoneal chemotherapy has lim...
Objective: This research endeavours to endorse the probable toxicity of tobramycin in terms of kidne...
Objectives: The present animal experiments were conducted to evaluate radioiodinated Hypericin (Hyp)...
Background/aims: We aimed to test clinical implications of intra-peritoneally administered gemcitabi...
Background: The incidence of oesophageal adenocarcinoma (OAC) continues to rise rapidly. There is a ...
Introduction. The aim of this study was to evaluate techniques and establish an optimal method for m...
AIM: To compare therapeutic responses of a vascular-disrupting-agent, combretastatin-A4-phosphate (C...
PURPOSE: Development of a lethal model of peritonitis to assess the results of treating that periton...
Aim: This study aimed to create a peritoneal metastasis (PM) model in Wistar albino rats and nude mi...
PURPOSE: To evaluate the biodistribution of sodium pertecnetate (Na99mTcO4) in organs and tissues, t...
There are many limitations for conducting liver disease research in human beings due to the high cos...
The small bowel transplantation (SBT) represents reasonable alternative to ultimate total parenteral...
Objectives: Presently, the results of small bowel transplantation (SBT) procedures are far from idea...
BACKGROUND/AIMS: In the animal model of auxiliary partial liver transplantation in the rat, the majo...
Contains fulltext : 80074.pdf (publisher's version ) (Closed access)Liver metastas...
Background: Peritoneal carcinomatosis is an unmet medical need. Intraperitoneal chemotherapy has lim...
Objective: This research endeavours to endorse the probable toxicity of tobramycin in terms of kidne...
Objectives: The present animal experiments were conducted to evaluate radioiodinated Hypericin (Hyp)...
Background/aims: We aimed to test clinical implications of intra-peritoneally administered gemcitabi...
Background: The incidence of oesophageal adenocarcinoma (OAC) continues to rise rapidly. There is a ...
Introduction. The aim of this study was to evaluate techniques and establish an optimal method for m...
AIM: To compare therapeutic responses of a vascular-disrupting-agent, combretastatin-A4-phosphate (C...